TABLE 1.

Dosages (median [IQR]) of the angiotensin converting enzyme inhibitors (ACEi) enalapril (E) and benazepril (B) and the angiotensin receptor blocker telmisartan (T) in 56 dogs

RASi treatment	Number of dogs	Dosage (mg/kg/d)	Final dosage (mg/kg/d)
No dose change—E	13	0.9 (0.6‐1.2)	n/a
No dose change—B	2	0.3 (0.2‐0.4)	n/a
No dose change—T	8	0.4 (0.4‐0.8)	n/a
Dose increase—E	9	0.5 (0.4‐0.8)	1.0 (0.6‐1.3)
Dose increase—B	4	0.4 (0.3‐0.8)	1.3 (0.5‐2.0)
Dose increase—T	5	0.5 (0.3‐0.7)	0.8 (0.5‐1.8)
Dose decrease—T	3	1.1 (0.8‐1.6)	0.6 (0.3‐1)

	Number of dogs	Dosage ACEi (mg/kg/d)	Dosage T (mg/kg/d)
Transition E to T	4	0.7 (0.3‐0.8)	0.5 (0.4‐0.9)
Transition B to T	5	0.5 (0.4‐0.7)	1 (0.7‐1.6)

	Number of dogs	Dosage ACEi (mg/kg/d)	Dosage T (mg/kg/d)
Both: E or B, plus T	3	1.46 (0.6‐2.0)	1.2 (0.7‐1.4)

Note: Twenty‐three dogs had no change in their monotherapy (no dose change), 18 dogs had a dose increase in their monotherapy (dose increase), 9 dogs transitioned from an ACEi to telmisartan (transition E/B to T), and 3 dogs received both an ACEi and telmisartan in combination on at least one study visit (E or B, plus T). Three dogs had a dosage decrease in telmisartan.